APPRAISE-2 Study with Investigational Compound Apixaban in Acute Coronary Syndrome Discontinued - Drugs.com MedNews
Links shared publicly online about this topic.
- 716total visits
APPRAISE-2 Study with Investigational Compound Apixaban in Acute Coronary Syndrome Discontinued - Drugs.com MedNews
Nov 18, 2010 - Bristol-Myers Squibb Company (NYSE BMY) and Pfizer (NYSE PFE) today reported that the companies have discontinued the Phase 3 APPRAISE-2 clinical
View full resource at drugs.com
Tags: Disease and Condition, Drug, Pfizer, Bristol-Myers Squibb
Most Recently Shared on November 19, 2010 at 3:08 pm By:
APPRAISE-2 Study with Investigational Compound Apixaban in Acute Coronary Syndrome Discontinued: PRINCETON... http://bit.ly/94rWRc #drug
APPRAISE-2 Study With Investigational Compound Apixaban In Acute Coronary Syndrome Discontinued
medicalnewstoday.com — “Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) today reported that the companies have discontinued the Phase 3 APPRAISE-2 clinical trial in patients with recent Acute Coronary Syn” View full resource at medicalnewstoday.com
Most Recently Shared on November 20, 2010 at 3:05 am By:
APPRAISE-2 Study With Investigational Compound Apixaban In Acute Coronary Syndrome Discontinued http://mnt.to/3MTp #heart #heartdisease
Advertisement
